WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), has launched WuXia™ RidGS, an advanced glutamine synthetase (GS)-knockout Chinese hamster ovary (CHO) expression system platform. Designed for antibiotic-free cell line development, this platform utilizes zinc finger nuclease (ZFN) technology for precise knockout of the endogenous GS gene in CHO cells.
Building on the established WuXia™ platform, WuXia™ RidGS combines robust cell growth, efficient metabolism, and high expression levels, with clonal expression for monoclonal antibodies (mAbs) exceeding 6 g/L on average. The platform ensures cell line stability across various therapeutic modalities, including bispecific antibodies, Fc-fusion proteins, and recombinant proteins. Protein products generated by WuXia™ RidGS feature favorable glycosylation and a high purity profile. Additionally, the antibiotic-free system supports stable productivity and consistent product quality in long-term cell line studies.
Dr. Chris Chen, CEO of WuXi Biologics, stated, “The launch of WuXia™ RidGS provides a more efficient solution for developing advanced therapeutic proteins. WuXi Biologics remains dedicated to creating specialized technology platforms to meet the evolving demands of our global clients, accelerating the development of life-saving therapies and enhancing access to high-quality biologics worldwide.
